Role of Lymphadenectomy in the Management of Early-Stage Endometrial Cancer

Objective This study aimed to determine the role of pelvic lymphadenectomy by assessing nodal positivity on progression-free and overall survival in early-stage endometrial cancer. Materials and methods Eighty-nine women diagnosed with stage I/II endometrial cancer at presentation who underwent pelvic lymphadenectomy during surgery from 2019 to 2023 were included in this retrospective study. Data was collected using the Hospital Information System (HIS), and patient identifiers were anonymized. In addition to patient characteristics, final histopathology including cytology, type of surgery (laparoscopic vs. open), radiological evidence of lymphadenopathy before surgery, number of lymph nodes retrieved, histopathological evidence of nodal-positive/nodal-negative disease, adjuvant therapy (if any), recurrence-free survival, and overall survival were noted for these patients. Analysis was done using IBM SPSS Statistics for Windows, Version 25.0 (Released 2017; IBM Corp., Armonk, New York, United States), with means and frequencies noted for descriptive variables. Recurrence-free survival and overall survival were estimated in months for patients with lymph node-positive and lymph node-negative disease. Results Fifty-eight (65.2%) patients underwent laparoscopic surgery in this study cohort with radiological evidence of lymphadenopathy in 17 patients. Only six patients were found to have nodal-positive disease, out of which only three had lymphadenopathy on scans. Forty-six (51.7%) patients received adjuvant radiation therapy, while 16 (18%) underwent adjuvant chemotherapy. The estimated mean survival was 65.6 months, with the recurrence-free survival being 61.7 months. Among the patients with lymph node-positive disease, only one was found to have disease recurrence despite adjuvant treatment. Conclusion This study elucidates that patients who underwent pelvic lymphadenectomy and were subsequently found to have nodal disease went on to receive adequate adjuvant therapy; however, for some of them, there was no specific preoperative indicator to prompt the decision for pelvic lymphadenectomy. Therefore, until advanced techniques such as sentinel lymph node mapping are available in low-resource countries, surgical staging with pelvic nodal sampling is recommended.

Authors

Institutions

Publication Details

Journal
Cureus
Published
2025-04-16
DOI
https://doi.org/10.7759/cureus.82408
Primary Topic
Endometrial and Cervical Cancer Treatments
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Role of Lymphadenectomy in the Management of Early-Stage Endometrial Cancer

Muhammad Usman, Kheyal Azam Khalil, Aamir Ali Syed, Sana Hussain et al.
1 links
Cureus
Endometrial and Cervical Cancer Treatments
article

Role of Lymphadenectomy in the Management of Early-Stage Endometrial Cancer

Muhammad Usman, Kheyal Azam Khalil, Aamir Ali Syed, Sana Hussain, Maria Habib
article en

Abstract

Objective This study aimed to determine the role of pelvic lymphadenectomy by assessing nodal positivity on progression-free and overall survival in early-stage endometrial cancer. Materials and methods Eighty-nine women diagnosed with stage I/II endometrial cancer at presentation who underwent pelvic lymphadenectomy during surgery from 2019 to 2023 were included in this retrospective study. Data was collected using the Hospital Information System (HIS), and patient identifiers were anonymized. In addition to patient characteristics, final histopathology including cytology, type of surgery (laparoscopic vs. open), radiological evidence of lymphadenopathy before surgery, number of lymph nodes retrieved, histopathological evidence of nodal-positive/nodal-negative disease, adjuvant therapy (if any), recurrence-free survival, and overall survival were noted for these patients. Analysis was done using IBM SPSS Statistics for Windows, Version 25.0 (Released 2017; IBM Corp., Armonk, New York, United States), with means and frequencies noted for descriptive variables. Recurrence-free survival and overall survival were estimated in months for patients with lymph node-positive and lymph node-negative disease. Results Fifty-eight (65.2%) patients underwent laparoscopic surgery in this study cohort with radiological evidence of lymphadenopathy in 17 patients. Only six patients were found to have nodal-positive disease, out of which only three had lymphadenopathy on scans. Forty-six (51.7%) patients received adjuvant radiation therapy, while 16 (18%) underwent adjuvant chemotherapy. The estimated mean survival was 65.6 months, with the recurrence-free survival being 61.7 months. Among the patients with lymph node-positive disease, only one was found to have disease recurrence despite adjuvant treatment. Conclusion This study elucidates that patients who underwent pelvic lymphadenectomy and were subsequently found to have nodal disease went on to receive adequate adjuvant therapy; however, for some of them, there was no specific preoperative indicator to prompt the decision for pelvic lymphadenectomy. Therefore, until advanced techniques such as sentinel lymph node mapping are available in low-resource countries, surgical staging with pelvic nodal sampling is recommended.

CureusVol. 17(4)
Shaukat Khanum Memorial Cancer Hospital and Research Center (PK)
Good health and well-being
Openalex Percentile: Top 89%
Endometrial and Cervical Cancer Treatments
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.